LONDON, October 30, 2018 /PRNewswire/ -- Multiple doses of AU-011 are well tolerated, with vision preservation observed at 12 to 18 months All Patients met preliminary efficacy endpoint to date with evidence of biological activity Aura plans to initiate a pivotal Pha...
from PR Newswire: //https://ift.tt/2SDkeQO
No comments:
Post a Comment